| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Procalcitonin
MessageRemove serum from gel or clot before transporting.
Test Code
PRCLN
Alias/See Also
Epic: LAB11144
CPT Codes
84145
Preferred Specimen
Specimen Type: Serum
Collection Container: Serum gel
Specimen Volume: 3 mL
Minimum Volume
0.3 mL
Instructions
Centrifuge and separate cells after clot formation and within 4 hours of collection. Remove serum if testing will be delayed more than 8 hours
Transport Container
Plastic vial
Specimen Stability
Room temperature (on gel): 8 hours
Room temperature (off gel): 24 hours
Refrigerated: 48 hours
Frozen: 15 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Samples stored on gel >8 hours, unlabeled, mislabeled, wrong tube type, hemolyzed, QNS, exceeds specimen stability requirements.
Methodology
Chemiluminescent Microparticle Immunoassay (CMIA)
Setup Schedule
Daily
Report Available
Same day
Reference Range
< 0.10 ng/mL
Clinical Significance
Used in conjunction with other laboratory findings and clinical
assessments, the ARCHITECT B∙R∙A∙H∙M∙S PCT assay is intended for use
as an:
• Aid in the risk assessment of critically ill patients on their first day of
intensive care unit (ICU) admission for progression to severe sepsis
and septic shock.
• Aid in assessing the cumulative 28-day risk of all-cause mortality for
patients diagnosed with severe sepsis or septic shock in the ICU or
when obtained in the emergency department or other medical wards
prior to ICU admission, using a change in PCT level over time.
• Aid in decision making on antibiotic therapy for patients with
suspected or confirmed lower respiratory tract infections (LRTI) –
defined as community-acquired pneumonia (CAP), acute bronchitis,
and acute exacerbation of chronic obstructive pulmonary disease
(AECOPD) – in an inpatient setting or an emergency department.
• Aid in decision making on antibiotic discontinuation for patients with
suspected or confirmed sepsis.
assessments, the ARCHITECT B∙R∙A∙H∙M∙S PCT assay is intended for use
as an:
• Aid in the risk assessment of critically ill patients on their first day of
intensive care unit (ICU) admission for progression to severe sepsis
and septic shock.
• Aid in assessing the cumulative 28-day risk of all-cause mortality for
patients diagnosed with severe sepsis or septic shock in the ICU or
when obtained in the emergency department or other medical wards
prior to ICU admission, using a change in PCT level over time.
• Aid in decision making on antibiotic therapy for patients with
suspected or confirmed lower respiratory tract infections (LRTI) –
defined as community-acquired pneumonia (CAP), acute bronchitis,
and acute exacerbation of chronic obstructive pulmonary disease
(AECOPD) – in an inpatient setting or an emergency department.
• Aid in decision making on antibiotic discontinuation for patients with
suspected or confirmed sepsis.
Performing Laboratory
Inova Laboratories
2832 Juniper Street
Fairfax, VA 22031
Last Updated: March 8, 2023
Last Review: N. Wolford, March 8, 2023